Rajneesh Nath, MD, discusses his hypothesis on the benefits of targeted delivery of Iomab-B to the marrow in the older relapsed or refractory acute myeloid leukemia population.
Rajneesh Nath, MD, a medical oncologist with Banner Health, discusses his hypothesis on the benefits of targeted delivery of Iomab-B to the marrow in the older relapsed or refractory acute myeloid leukemia (AML) population. His findings were presented at the 2021 Transplantation & Cellular Therapy Meetings.
According to Nath, the 2 most common types of stem cell transplantation are myeloablation and reduced intensity. Myeloablation is associated with increased intensity of chemotherapy and higher doses of radiation. This tends to increase the toxicity of treatment for the patient.
Nath’s hypothesis that delivery of Iomab-B directly to where it is needed can help reduce toxicity and save critical organs such as the heart, lungs and kidney. The study found that Iomab-B was able to spare the gastrointestinal tract. According to Nath, instances of sepsis in the Iomab-B group was 4% while in the standard of care group, it was 13%.
Nivolumab Plus Chemo Improves OS in Chinese Patients With Advanced Gastric/GEJ Cancer
January 23rd 2025The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in Chinese patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma.
Read More
5-Year Update Sustains Nivolumab/Chemo Efficacy in Frontline Gastric/GEJ/Esophageal Cancer
January 23rd 20255-year follow-up results from the phase 3 CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.
Read More
First Dose of CD38-Targeting CAR T-Cell Therapy Administered in AML
January 22nd 2025The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy targeting CD38 and developed using the THANK-uCAR platform, in an investigator-initiated trial in China.
Read More